United Therapeutics 관리
관리 기준 확인 2/4
United Therapeutics CEO는 Martine Rothblatt, Jan1996 에 임명되었습니다 의 임기는 28.83 년입니다. 총 연간 보상은 $ 16.96M, 8.7% 로 구성됩니다. 8.7% 급여 및 91.3% 보너스(회사 주식 및 옵션 포함). 는 $ 242.22M 가치에 해당하는 회사 주식의 1.49% 직접 소유합니다. 242.22M. 경영진과 이사회의 평균 재임 기간은 각각 15.6 년과 22.2 년입니다.
주요 정보
Martine Rothblatt
최고 경영자
US$17.0m
총 보상
| CEO 급여 비율 | 8.7% |
| CEO 임기 | 28.8yrs |
| CEO 소유권 | 1.5% |
| 경영진 평균 재임 기간 | 15.6yrs |
| 이사회 평균 재임 기간 | 22.2yrs |
최근 관리 업데이트
Recent updates
United Therapeutics: One To Believe In Despite Competitive Threats
Nov 14Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$17m | US$1m | US$985m |
| Sep 30 2023 | n/a | n/a | US$900m |
| Jun 30 2023 | n/a | n/a | US$872m |
| Mar 31 2023 | n/a | n/a | US$728m |
| Dec 31 2022 | US$5m | US$1m | US$727m |
| Sep 30 2022 | n/a | n/a | US$707m |
| Jun 30 2022 | n/a | n/a | US$631m |
| Mar 31 2022 | n/a | n/a | US$687m |
| Dec 31 2021 | US$4m | US$1m | US$476m |
| Sep 30 2021 | n/a | n/a | US$462m |
| Jun 30 2021 | n/a | n/a | US$471m |
| Mar 31 2021 | n/a | n/a | US$405m |
| Dec 31 2020 | US$5m | US$1m | US$515m |
| Sep 30 2020 | n/a | n/a | US$469m |
| Jun 30 2020 | n/a | n/a | US$430m |
| Mar 31 2020 | n/a | n/a | US$528m |
| Dec 31 2019 | US$46m | US$1m | -US$104m |
| Sep 30 2019 | n/a | n/a | -US$92m |
| Jun 30 2019 | n/a | n/a | -US$118m |
| Mar 31 2019 | n/a | n/a | -US$150m |
| Dec 31 2018 | US$16m | US$1m | US$589m |
| Sep 30 2018 | n/a | n/a | US$543m |
| Jun 30 2018 | n/a | n/a | US$713m |
| Mar 31 2018 | n/a | n/a | US$484m |
| Dec 31 2017 | US$37m | US$1m | US$418m |
보상 대 시장: Martine 의 총 보상 ($USD 16.96M )은 US 시장( $USD 12.74M ).
보상과 수익: Martine 의 보상은 지난 1년 동안 20% 이상 증가했습니다.
CEO
Martine Rothblatt (69 yo)
28.8yrs
테뉴어
US$16,958,057
보상
Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Founder | 28.8yrs | US$16.96m | 1.49% $ 242.2m | |
| President & COO | 8.4yrs | US$9.81m | 0.0058% $ 935.7k | |
| CFO & Treasurer | 11.8yrs | US$6.05m | 0.018% $ 2.9m | |
| Executive VP | 28.8yrs | US$5.15m | 0.082% $ 13.3m | |
| Head of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Associate Vice President of Human Resources | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Strategic Operations & Logistics | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP of Technical Operations | 15.6yrs | 데이터 없음 | 데이터 없음 | |
| Executive Vice President of Product Development & Xenotransplantation | no data | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Medical Officer | no data | 데이터 없음 | 데이터 없음 |
15.6yrs
평균 재임 기간
56yo
평균 연령
경험이 풍부한 관리: UTHR 의 관리팀은 노련하고 경험 (평균 재직 기간 15.6 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Founder | 28.8yrs | US$16.96m | 1.49% $ 242.2m | |
| Member of the Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 22.8yrs | US$457.60k | 0.027% $ 4.4m | |
| Independent Director & Member of the Scientific Advisory Board | 22.2yrs | US$471.54k | 0.029% $ 4.7m | |
| Independent Director & Member of the Scientific Advisory Board | 22.8yrs | US$456.54k | 0.0039% $ 635.7k | |
| Independent Vice Chairman & Lead Independent Director | 22.1yrs | US$532.60k | 0.0045% $ 726.5k | |
| Independent Director | 21.3yrs | US$481.54k | 0.0082% $ 1.3m | |
| Member of the Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 22.8yrs | US$456.54k | 0.050% $ 8.2m | |
| Member of the Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 9.4yrs | US$488.66k | 0.013% $ 2.1m | |
| Independent Director | 15.6yrs | US$513.66k | 0.039% $ 6.3m |
22.2yrs
평균 재임 기간
76yo
평균 연령
경험이 풍부한 이사회: UTHR 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 22.2 년).